HOME >> MEDICINE >> NEWS
Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

BRIDGEWATER, NJ - June 7, 2004 - Aventis (NYSE: AVE) announced today that the results of two landmark phase III trials using Taxotere® (docetaxel) Injection Concentrate based regimens in the treatment of androgen-independent (hormone-refractory) metastatic prostate cancer have been presented at the plenary session of the annual meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, LA.

The clinical trials TAX 327 and SWOG 9916, were led by investigators from the Johns Hopkins Kimmel Cancer Center and NewYork-Presbyterian Hospital/Columbia University Medical Center and the Southwest Oncology Group (SWOG). The trials involved nearly 1,800 patients and demonstrated that Taxotere®-based regimens significantly reduced the risk of death by 24 percent and 20 percent, respectively. Investigators in the TAX 327 trial also reported that Taxotere® significantly improved patients' PSA responses by 43 percent (p=0.0005) and improved pain responses by 59 percent (p=0.0107), relative to mitoxantrone response rates.

The SWOG trial investigators reported a 27 percent increase in disease-progression-free survival and a 55 percent increase in objective response rate in the Taxotere®-containing arm. In addition, the majority of patients had a PSA decline of more than 50 percent.

"These studies are the first to show that a chemotherapy agent, Taxotere®, can deliver a significant survival benefit in androgen-independent (hormone-refractory) metastatic prostate cancer patients, giving hope to thousands of men worldwide," said Daniel Petrylak, MD, Associate Professor of Medicine at Columbia University College of Physicians & Surgeons, Director of the Genitourinary Oncology Program at NewYork-Presbyterian Hospital. "These data represent an important new treatment option for men with prostate cancer because it can help some patients live longer."

Prostate cancer ranks third worldwide in cancer incidence
'"/>

Contact: Lisa Kennedy, Aventis
lisa.a.kennedy@aventis.com
908-243-6361
Porter Novelli
7-Jun-2004


Page: 1 2 3 4

Related medicine news :

1. The Hospital of the University of Pennsylvania evaluates heart failure treatments for landmark study
2. Mayo Clinic establishes landmark research program to predict and prevent alcoholism
3. UCLA seeks thousands of current and former smokers for landmark lung cancer screening trial
4. New studies suggest airborne SARS transmission is possible
5. New studies show mixed results on epilepsy drugs and birth defects
6. Brain imaging studies investigate pain reduction by hypnosis
7. Impact of scientific advances on drug studies and membrane research to be explored
8. Two studies find evidence that sunlight may have beneficial influence on cancer
9. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
10. Animal studies show stem cells might make biological pacemaker
11. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United ... year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and ... havens have extremely low property-tax rates, which contributes to the relatively lower cost ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
Breaking Medicine Technology:
Cached News: